Knight Therapeutics Inc. (OTCMKTS:KHTRF – Get Free Report)’s stock price shot up 0.6% during mid-day trading on Monday. The stock traded as high as $7.22 and last traded at $7.22. Approximately 1,700 shares changed hands during mid-day trading, a decline of 78% from the average daily volume of 7,792 shares. The stock had previously closed at $7.18.
Wall Street Analysts Forecast Growth
Separately, Royal Bank Of Canada restated an “outperform” rating on shares of Knight Therapeutics in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, Knight Therapeutics currently has an average rating of “Buy”.
Read Our Latest Research Report on Knight Therapeutics
Knight Therapeutics Price Performance
About Knight Therapeutics
Knight Therapeutics Inc is a Canadian specialty pharmaceutical company focused on acquiring, licensing, commercializing and, in some cases, developing innovative medicines. The company concentrates on therapies that address unmet medical needs, including specialty, orphan and hospital-based treatments.
Through licensing and commercialization agreements, Knight offers a portfolio of prescription products across therapeutic areas such as oncology, rare diseases, infectious diseases and neurology.
Further Reading
- Five stocks we like better than Knight Therapeutics
- Six Flags Launches FlexPay—Is There Any FUN Left in the Stock?
- Brewing Trouble? Starbucks Spills the Beans on 250 Store Closures
- Stitch Fix Stock Plunges as Guidance Puts the Turnaround on Pause
- Harley-Davidson Insiders Are Buying: Is HOG Finally Turning Around?
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
